Travere Therapeutics, Inc. (TVTX) Balance Sheet
As of 2026-06-30 (10-Q), Travere Therapeutics, Inc. (TVTX) reported total assets of $799.4M, total liabilities of $774.8M and shareholders' equity of $24.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $117.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TVTXTravere Therapeutics, Inc.Follow TVTX — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2011 Dec 11 | FY2012 Feb 12 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.0 | — | 0.0 | 6.0 | 18.2 | 37.8 | 41.0 | 99.4 | 102.9 | 62.4 | 84.8 | 165.8 | 61.7 | 58.2 | 58.5 | 93.0 | 117.7 | |
| Short-term investments | — | — | — | 0.1 | 9.6 | 191.8 | 214.9 | 123.3 | 208.5 | 209.5 | 271.8 | 262.2 | 285.5 | 248.6 | — | 145.4 | 175.9 | |
| Receivables | — | — | — | — | 8.0 | 12.5 | 18.5 | 13.9 | 12.7 | 18.0 | 15.9 | 15.9 | 16.6 | 21.2 | 27.1 | 80.1 | 80.6 | |
| Inventory | — | — | — | — | 0.8 | 2.5 | 2.8 | 5.4 | 5.6 | 6.1 | 7.6 | 7.3 | 4.5 | 9.4 | 41.9 | 36.2 | 40.0 | |
| Current assets | 0.0 | 0.0 | 0.0 | 7.5 | 37.3 | 301.9 | 332.4 | 325.8 | 495.7 | 429.1 | 410.4 | 582.8 | 486.4 | 616.8 | 416.7 | 437.6 | 615.1 | |
| Total assets | 0.0 | 0.0 | 2.4 | 20.5 | 135.5 | 512.3 | 525.3 | 520.3 | 709.2 | 604.8 | 607.4 | 776.6 | 672.6 | 788.9 | 594.1 | 605.2 | 799.4 | |
| Current liabilities | 0.6 | 0.1 | 5.8 | 36.6 | 107.5 | 87.0 | 83.3 | 85.7 | 104.6 | 95.4 | 92.7 | 124.1 | 142.2 | 177.9 | 200.8 | 159.9 | 152.0 | |
| Long-term debt | — | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Total liabilities | — | — | 5.8 | 40.2 | 172.7 | 212.3 | 217.5 | 227.2 | 390.9 | 383.6 | 396.2 | 474.5 | 629.7 | 588.1 | 535.0 | 490.4 | 774.8 | |
| Shareholders' equity | -0.5 | -0.1 | -3.4 | -19.7 | -37.3 | 300.0 | 307.8 | 293.1 | 318.3 | 221.2 | 211.2 | 302.1 | 42.9 | 200.8 | 59.1 | 114.8 | 24.5 |
USD millions · SEC XBRL
Travere Therapeutics, Inc. — questions
- How much cash does Travere Therapeutics, Inc. have?
- $117.7M in cash and cash equivalents as of 2026-06-30.
- What are Travere Therapeutics, Inc.'s total assets?
- $799.4M as of 2026-06-30.
- What is Travere Therapeutics, Inc.'s shareholders' equity?
- $24.5M as of 2026-06-30.
Every figure on this page comes from Travere Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.